Navigation Links
Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting
Date:11/10/2011

onal prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the teratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA's response to the NDA filed for avanafil; our ability to successfully commercialize or establish a marketing partnership for avanafil or our partner's ability to obtain regulatory approval to manufacture and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing efforts and our reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of ini
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
2. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
3. Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
4. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
5. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
6. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
7. LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference
8. Discovery Labs Releases New AFECTAIR™ Performance Data Presented at the American Association for Respiratory Care Annual Meeting
9. Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine
10. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
11. Bayer HealthCares MEDRAD Interventional Business Announces Five-Year Data of Cotavance® Drug Eluting Balloon with Paccocath® Technology to be Presented at 2011 TCT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... On Tuesday, July 1, 2014, ... the 116 th Judicial District Court in ... RegenLab USA, LLC ("Defendant") for Tortious ... through false and misleading actions, fraud, fraud-in-the-inducement, business ... through libel, disparagement, defamation, misrepresentation, and violating the ...
(Date:7/23/2014)... Creekridge Capital, an independent vendor-focused finance ... so far in 2014 to their portfolio of ... from both the healthcare and technology industries. They ... multi-national companies. Each of these new vendors take ... including: standard leasing products, subscription solutions, a dedicated ...
(Date:7/23/2014)...  Mezzion Pharma Co. Ltd., announced that it has ... udenafil to treat adolescents who have undergone the Fontan ... program will follow protocols developed by a subcommittee made ... a multi-center clinical research network funded by the National ... Institutes of Health (NIH). The studies, ...
Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2
... (Nasdaq: BMRN ) today hosted a Research ... team and industry experts provided an update on BioMarin,s ... pipeline. "We believe 2011 has been a ... and early stage clinical development programs," said Jean-Jacques Bienaime, ...
... Modern Materials Division of Heraeus Kulzer, LLC, the ... The division has been the leader in the U.S. dental ... Modern Materials was founded in 1946 in St. Louis, ... chemist, was "Mr. Inside" while Mr. Piper, the consummate salesman, ...
Cached Medicine Technology:Highlights from BioMarin's Research & Development Day 2Highlights from BioMarin's Research & Development Day 3Highlights from BioMarin's Research & Development Day 4Highlights from BioMarin's Research & Development Day 5Highlights from BioMarin's Research & Development Day 6Heraeus' Modern Materials Division Celebrates 65th Anniversary 2Heraeus' Modern Materials Division Celebrates 65th Anniversary 3
(Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... Many obese and overweight American children and teens look ... fine, U.S. health officials reported Wednesday. "Being overweight ... as high blood pressure, high cholesterol and diabetes," said ... U.S. Centers for Disease Control and Prevention,s National Center ...
(Date:7/23/2014)... The next episode of “Extreme Weight Loss” ... was physically fit through childhood and adolescence. After becoming ... heart-wrenching decision to give her son up for adoption. ... years, and she punished herself by overeating, gaining nearly ... non-competitive approach to weight loss transformations, “Extreme Weight Loss” ...
(Date:7/23/2014)... 23, 2014 Home Care Assistance ... for seniors, is proud to announce the next installment ... in a wide range of health and wellness-related fields. ... and award-winning author Nancy Kriseman, and will cover the ... prevent burnout by becoming more self-aware. In particular, Nancy ...
(Date:7/23/2014)... Painful or itchy skin lesions could be a warning ... have multiple lesions that are suspicious looking, and those ... for non-melanoma skin cancers," study author Dr. Gil Yosipovitch, ... said in a Temple University Health System news release. ... patients who were confirmed to have skin cancer lesions ...
(Date:7/23/2014)... supports a growing body of research suggesting a ... in treating postmenopausal breast cancer, with fewer detrimental ... standard anti-hormone therapies. The study will be published ... Reproductive Biology and Endocrinology . , Breast ... women in the United States. Approximately 70% of ...
Breaking Medicine News(10 mins):Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5
... Amanda Gardner HealthDay Reporter , FRIDAY, Dec. 16 ... who receive targeted radiation to the breast after a lumpectomy ... only about a third of these women were considered "suitable" ... study published in the Dec. 16 online issue of the ...
... SAGE and the European Society of Cardiology (ESC) ... Journal: Acute Cardiovascular Care. The first issue will be ... represents over 70,000 cardiology professionals across Europe and the ... including publishing seven of the world,s leading cardiology journals. ...
... 17 (HealthDay News) -- The busy holiday season may disrupt ... it is especially important to remember to look after your ... people to consume sugary treats and drink alcoholic beverages more ... General Dentistry, said in an academy news release. "Additionally, ...
... Will a drug used to treat childhood acute lymphoblastic leukemia ... UB associate professor of pharmaceutical sciences, Javier G. ... research and clinical practice, has focused recent efforts on trying ... study in the Journal of Clinical Oncology looked for the ...
... Scientists may have a way to double the efficacy ... Sciences University scientists have devised a way to reduce lung ... caused by radiation therapy., "Radiation is a great therapy ... Dynan, biochemist and Associate Director of Research and Chief, Nanomedicine ...
... FRIDAY, Dec. 16 (HealthDay News) -- Chronic pain can ... the affected partner,s ability to cope with the pain, ... shown that validation of a spouse,s emotions (showing respect ... invalidation of emotions (showing hostility or no interest) increases ...
Cached Medicine News:Health News:Targeted Radiation for Breast Cancer May Be Overused: Study 2Health News:Targeted Radiation for Breast Cancer May Be Overused: Study 3Health News:Sage and European Society of Cardiology extend publishing partnership 2Health News:Dentist Gives Advice to Keep Holiday Smiles Bright 2Health News:Childhood cancer drugs cure now, may cause problems later, UB research shows 2Health News:Scientists may be able to double efficacy of radiation therapy 2Health News:Spouse's Reaction May Affect Pain Management 2
Large image and wide-angle design....
Large-image field with titanium couplers for c-mount scopes. 30mm focal length....
High intensity lamp with built-in, switchable spare lamp. Low-noise fan with reduced air turbulence....
PDA application listing specific ICD-9 coding listed in new Medicare National Coverage Determinations....
Medicine Products: